|
Mar 7
|
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 7
|
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
|
|
Mar 4
|
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 10
|
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
|
|
Nov 7
|
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
|
|
Nov 2
|
Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Nov 2
|
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition
|
|
Jul 31
|
The past three years for Poseida Therapeutics (NASDAQ:PSTX) investors has not been profitable
|